Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 2, 2016, Pages 251-258.e2

  Brandse, Johannan F ^a   Mathôt, Ron A ^a   van der Kleij, Desiree ^b   Rispens, Theo ^c   Ashruf, Yaël ^a   Jansen, Jeroen M ^d   Rietdijk, Svend ^d   Löwenberg, Mark ^a   Ponsioen, Cyriel Y ^a   Singh, Sharat ^e   van den Brink, Gijs R ^a   D'Haens, Geert R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c SANQUIN RESEARCH   (Netherlands)

^d ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^e Prometheus Laboratories   (United States)

Author keywords

Anti TNF; IBD; Response to Treatment; Tumor Necrosis Factor

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALGRANULIN; INFLIXIMAB; ANTIBODY; IMMUNOLOGIC FACTOR;

ADULT; ALBUMIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CENTRAL VOLUME OF DISTRIBUTION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FECES LEVEL; DRUG HALF LIFE; FECES LEVEL; FEMALE; HUMAN; MALE; NETHERLANDS; PERIPHERAL VOLUME OF DISTRIBUTION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMISTRY; COLITIS, ULCERATIVE; SERUM; TREATMENT OUTCOME;

ADULT; ANTIBODIES; COLITIS, ULCERATIVE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFLIXIMAB; MALE; NETHERLANDS; PROSPECTIVE STUDIES; SERUM; TREATMENT OUTCOME;

EID: 84959010224     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.10.029     Document Type: Article

References (30)

1. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
2. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
3. Maser E.A., Villela R., Silverberg M.S., et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
4. Seow C.H., Newman A., Irwin S.P., et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010, 59:49-54.
5. Laharie D., Bourreille A., Branche J., et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012, 380:1909-1915.
6. Adedokun O.J., Sandborn W.J., Feagan B.G., et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology 2014, 147:1296-1307 e5.
7. Fasanmade A.A., Adedokun O.J., Ford J., et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 2009, 65:1211-1228.
8. Kevans D, Murthy S, Iacono A, et al. Sa2031 accelerated clearance of serum infliximab during induction therapy for acute ulcerative colitis is associated with treatment failure. Gastroenterology 142;5:S-384-385.
9. Brandse J.F., van den Brink G.R., Wildenberg M.E., et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology 2015, 149:350-355.
10. Gibson D.J., Heetun Z.S., Redmond C.E., et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015, 13:330-335.
11. Walmsley R.S., Ayres R.C., Pounder R.E., et al. A simple clinical colitis activity index. Gut 1998, 43:29-32.
12. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987, 317:1625-1629.
13. Wolbink G.J., Vis M., Lems W., et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:711-715.
14. Bartelds G.M., Krieckaert C.L., Nurmohamed M.T., et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011, 305:1460-1468.
15. Vande C.N., Buurman D.J., Sturkenboom M.G., et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012, 36:765-771.
16. Wang S.L., Ohrmund L., Hauenstein S., et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods 2012, 382:177-188.
17. Vermeire S., Noman M., Van A.G., et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007, 56:1226-1231.
18. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
19. Jarvis J.N., Xu C., Wang W., et al. Immune complex size and complement regulate cytokine production by peripheral blood mononuclear cells. Clin Immunol 1999, 93:274-282.
20. van Schie Kak S., Hart M., D'Haens G.R., et al. The biological effect of immune complexes in infusion reactions towards infliximab 2015, Sanquin, Amsterdam, The Netherlands.
21. Solem C.A., Loftus E.V., Tremaine W.J., et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005, 11:707-712.
22. Fasanmade A.A., Adedokun O.J., Olson A., et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 2010, 48:297-308.
23. Dotan I., Ron Y., Yanai H., et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis 2014, 20:2247-2259.
24. Mould D.R., Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs 2010, 24:23-39.
25. Kapel N., Meillet D., Favennec L., et al. Evaluation of intestinal clearance and faecal excretion of alpha 1-antiproteinase and immunoglobulins during Crohn's disease and ulcerative colitis. Eur J Clin Chem Clin Biochem 1992, 30:197-202.
26. Nestorov I. Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol Suppl 2005, 74:13-18.
27. Yarur A.J., Jain A., Sussman D.A., et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut 2015, [Epub ahead of print].
28. Jonsson E.N., Karlsson M.O. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999, 58:51-64.
29. Keizer R.J., van Benten M., Beijnen J.H., et al. Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed 2011, 101:72-79.
30. Karlsson M.O., Savic R.M. Diagnosing model diagnostics. Clin Pharmacol Ther 2007, 82:17-20.